| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
2',3'-cUMP sodium acts as a competitive inhibitor of ribonuclease A (RNase A). By binding to the active site of the enzyme, it prevents the enzyme from binding to and cleaving RNA. Specifically, it is a transition-state analog, meaning it mimics the geometry and charge of the RNA molecule as it is being hydrolyzed, leading to tight binding to the enzyme's active site. It is also a competitive inhibitor of di-p-nitrophenyl phosphate hydrolysis.
|
|---|---|
| ln Vitro |
In vitro, 2',3'-cUMP is used in enzyme kinetics assays to inhibit the activity of RNase A. The inhibition constant (Ki) can be determined by measuring the enzyme's activity in the presence of varying concentrations of the inhibitor. It is also used to study the mechanism of RNA hydrolysis by providing a stable analog of the transition state. Its activity is not typically evaluated on whole cells, as it is a nucleotide analog that may have multiple effects.
|
| ln Vivo |
No specific in vivo activity data is reported. As a nucleotide analog, it could potentially interfere with cellular nucleic acid metabolism if administered in vivo. It shows promise in research for the treatment of cancer and viral infections, but this is at the stage of in vitro research only. No approved or widely studied in vivo animal models are documented for this compound.
|
| Enzyme Assay |
The standard assay for RNase A is performed in a 96-well plate. The reaction mixture (100 uL) contains 50 mM Tris-HCl (pH 7.5), 0.1 mg/mL BSA, and a fluorogenic RNA substrate (e.g., 0.5 uM of an RNAseAlert Substrate). 2',3'-cUMP is added at varying concentrations (0-1 mM). The reaction is initiated by adding 0.1-1 nM of RNase A. The increase in fluorescence (e.g., Ex/Em 490/520 nm) is measured over 15-60 minutes to determine the initial reaction rate. The Ki is calculated by fitting the data to a competitive inhibition model.
|
| Cell Assay |
2',3'-cUMP is a cell-permeable nucleotide analog, but it is not typically used in standard cell-based viability assays. For research, it could be added to the culture media of cancer cells at concentrations of 10-100 uM. After 24-72 hours, the effect on cell growth would be measured by MTT assay. However, its effect may be indirect, through inhibition of cellular RNases, and such uses are not standard. It can also be used as a standard in HPLC to quantify cyclic nucleotides in biological extracts.
|
| Animal Protocol |
No standard in vivo protocols exist for 2',3'-cUMP. As a potential anti-cancer lead, a xenograft mouse model could be used. The compound would be formulated in PBS and administered intraperitoneally or intravenously at a dose of 10-50 mg/kg. Tumor volume would be measured over 2-4 weeks, but such data is not available for this compound.
|
| ADME/Pharmacokinetics |
No specific pharmacokinetic data is available for 2',3'-cUMP sodium. As a sodium salt, it is water-soluble and soluble in DMSO. The compound is a cyclic phosphate, which is more stable than linear phosphates but can still be hydrolyzed by phosphodiesterases. For research, the compound is stored as a powder at -20degC, and solutions are prepared fresh in water or buffer. Its stability in plasma is unknown.
|
| Toxicity/Toxicokinetics |
No specific toxicology data is available. As a modified nucleotide, it is not expected to be highly toxic, but standard laboratory safety precautions should be followed. The compound may be a skin, eye, and respiratory tract irritant. Avoid inhalation, ingestion, and skin contact. It is strictly for research use only and not for human or veterinary use.
|
| References | |
| Additional Infomation |
2',3'-cUMP sodium is a cyclic nucleotide analog used as a research tool to study the mechanism of RNA hydrolysis. It is a transition-state analog and competitive inhibitor of RNase A. The compound has potential research applications in cancer and virology but is not a drug and has no approved therapeutic use.
|
| Molecular Formula |
C9H10N2NAO8P
|
|---|---|
| Molecular Weight |
328.15
|
| Exact Mass |
328.007
|
| CAS # |
15718-50-0
|
| Related CAS # |
606-02-0 (Parent)
|
| PubChem CID |
44755149
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.85 g/cm3
|
| Index of Refraction |
1.65
|
| Source |
Originated from microorganisms: Proteus mirabilis
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
21
|
| Complexity |
542
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=CN(C(=O)NC1=O)[C@H]2[C@H]3[C@@H]([C@H](O2)CO)OP(=O)(O3)[O-].[Na+]
|
| InChi Key |
LXUDDBXIXSYSRT-IAIGYFSYSA-M
|
| InChi Code |
InChI=1S/C9H11N2O8P.Na/c12-3-4-6-7(19-20(15,16)18-6)8(17-4)11-2-1-5(13)10-9(11)14;/h1-2,4,6-8,12H,3H2,(H,15,16)(H,10,13,14);/q;+1/p-1/t4-,6-,7-,8-;/m1./s1
|
| Chemical Name |
sodium;1-[(3aR,4R,6R,6aR)-6-(hydroxymethyl)-2-oxido-2-oxo-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3,2]dioxaphosphol-4-yl]pyrimidine-2,4-dione
|
| Synonyms |
Uridine-2', 3'-cyclic monophosphate sodium salt
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0474 mL | 15.2369 mL | 30.4739 mL | |
| 5 mM | 0.6095 mL | 3.0474 mL | 6.0948 mL | |
| 10 mM | 0.3047 mL | 1.5237 mL | 3.0474 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
